Saturday 17 October 2026
Export HOWL’s income statement to Excel — free account
Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
0.98
0.02
−2.00%
Follow HOWL
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 10.69 | 1.39 | 1.57 | 1.38 | 0.56 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 23.99 | 12.86 | 4.57 | 8.19 | 2.38 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 24 | 39 | 46 | 47 | 46 | 39 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.36 | 0.42 | 0.04 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 16 | 20 | 2 | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | — | |||||
| EBT | — | — | — | (10) | (15) | (50) | (54) | (37) | (71) | (61) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | (328.09) | (187.37) | (3,740.85) | 0.00 | |||||
| Net income | — | 0 | — | (10) | (15) | (50) | (54) | (37) | (71) | (61) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 1 | 2 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.57 | 0.56 | 0.04 | 0.00 | ||||
| Earnings | — | — | — | (16.01) | (14.97) | (10.94) | (1.86) | (1.05) | (1.63) | (1.32) | |||||
| Cash flow | — | — | — | (14.91) | (18.53) | (2.32) | (1.41) | (0.91) | (1.30) | (1.31) | |||||
| Capex | — | — | — | (0.42) | (0.56) | (0.03) | (0.13) | (0.02) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | (15.32) | (19.09) | (2.35) | (1.53) | (0.94) | (1.30) | (1.31) | |||||
| Book value | — | — | — | (37.97) | (51.60) | 8.28 | 4.24 | 3.12 | 1.69 | 0.54 | |||||
| Shares, m | — | — | — | 1 | 1 | 18 | 29 | 36 | 43 | 46 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | 0.00 | 8.29 | 6.91 | — | |||||
| P/B | — | — | — | — | — | — | 0.48 | 1.49 | 0.87 | — | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 3.19 | (2.24) | — | |||||
| EV/FCF | — | — | — | — | — | — | 1.30 | (1.91) | 0.37 | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (10) | (19) | (43) | (41) | (33) | (56) | (60) | ||||
| Capex | — | — | — | 0 | (1) | 0 | (4) | (1) | 0 | — | |||||
| Free cash flow | — | — | — | (10) | (19) | (43) | (44) | (33) | (56) | (60) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 16 | 88 | 149 | 116 | 119 | 98 | 22 | ||||
| Total debt | — | — | — | 10 | 2 | 15 | 13 | 33 | 26 | — | |||||
| Net debt | — | — | — | (8) | (91) | (143) | (117) | (102) | (85) | (57) | |||||
| Shareholders’ equity | — | — | — | (24) | (52) | 153 | 122 | 111 | 73 | 25 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (168.17) | (47.79) | (146.51) | (31.70) | (22.30) | (46.74) | (61.96) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (317.97) | (623.18) | (261.32) | 0.00 | 0.00 | |||||
| ROE | — | — | — | 47.87 | 74.09 | (400.15) | (39.12) | (31.98) | (76.33) | (123.88) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Jun 2026
Charts ten years each
Werewolf Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LONA LeonaBio, Inc. | $49.8M | — (loss-making) | — | — | n/m | −142.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CRBU Caribou Biosciences, Inc. | $49.8M | — (loss-making) | — (loss-making) | −43.79% (below 0%: shrinking) | n/m | −33.16% (below 0%: shrinking) | 100.00% | (1,690.39%) | Compare |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $49.3M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HYPD Hyperion DeFi, Inc. | $49.0M | — (loss-making) | 3.6× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $48.5M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | |
| ELTX Elicio Therapeutics, Inc. | $48.2M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ACET Adicet Bio, Inc. | $48.1M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $47.8M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IBIO iBio, Inc. | $47.6M | — (loss-making) | — (loss-making) | +100.00% (above 0%: growing) | n/m | −35.33% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $48.6M | — | — | +100.00% | — | +10.34% | 0.00% | 0.00% |
Werewolf Therapeutics, Inc. (HOWL) key facts
- Concern: Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023.
- Werewolf Therapeutics, Inc. (HOWL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, HOWL traded at $0.98, a market capitalization of $48.5 million.
- Return on equity was −123.9% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.83 (distress zone) for fiscal 2024.